Literature DB >> 15889991

Acellular pertussis vaccines in Japan: past, present and future.

Mineo Watanabe1, Masaaki Nagai.   

Abstract

An antivaccine movement developed in Japan as a consequence of increasing numbers of adverse reactions to whole-cell pertussis vaccines in the mid-1970s. After two infants died within 24 h of the vaccination from 1974 to 1975, the Japanese government temporarily suspended vaccinations. Subsequently, the public and the government witnessed the re-emergence of whooping cough, with 41 deaths in 1979. This series of unfortunate events revealed to the public that the vaccine had, in fact, been beneficial. Furthermore, researchers and the Japanese government proceeded to develop safer pertussis vaccines. Japan now has the most experience worldwide with acellular pertussis vaccines, being the first country to have approved their use. This review describes the major events associated with the Japanese vaccination program. The Japanese experience should be valuable to other countries that are considering the development and use of such vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889991     DOI: 10.1586/14760584.4.2.173

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  14 in total

1.  Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries.

Authors:  H Broutin; C Viboud; B T Grenfell; M A Miller; P Rohani
Journal:  Proc Biol Sci       Date:  2010-06-09       Impact factor: 5.349

Review 2.  The first steps towards the era of personalised vaccinology: predicting adverse reactions.

Authors:  P Pellegrino; F S Falvella; V Perrone; C Carnovale; T Brusadelli; M Pozzi; S Antoniazzi; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

Review 3.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

Review 4.  Economical value of vaccines for the developing countries--the case of Instituto Butantan, a public institution in Brazil.

Authors:  Paulo Lee Ho; Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Waldely de Oliveira Dias; Flavia Saldanha Kubrusly; Martha Massako Tanizaki; Elizabeth Angélica Leme Martins; Isaias Raw
Journal:  PLoS Negl Trop Dis       Date:  2011-11-29

5.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

6.  Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?

Authors:  Audrey J King; Tamara van Gorkom; Han G J van der Heide; Abdolreza Advani; Saskia van der Lee
Journal:  BMC Genomics       Date:  2010-01-26       Impact factor: 3.969

7.  The epidemiology of pertussis in Germany: past and present.

Authors:  Wiebke Hellenbrand; Dietmar Beier; Evelin Jensen; Martina Littmann; Christiane Meyer; Hanna Oppermann; Carl-Heinz Wirsing von König; Sabine Reiter
Journal:  BMC Infect Dis       Date:  2009-02-25       Impact factor: 3.090

8.  Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network.

Authors:  Eve Dubé; Dominique Gagnon; Manale Ouakki; Julie A Bettinger; Maryse Guay; Scott Halperin; Kumanan Wilson; Janice Graham; Holly O Witteman; Shannon MacDonald; William Fisher; Laurence Monnais; Dat Tran; Arnaud Gagneur; Juliet Guichon; Vineet Saini; Jane M Heffernan; Samantha Meyer; S Michelle Driedger; Joshua Greenberg; Heather MacDougall
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

9.  Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.

Authors:  Nihal M Ibrahim; Ebtsam M El-Kady; Somiaa A Eissa; Ahmed F Wahby
Journal:  J Adv Res       Date:  2015-03-21       Impact factor: 10.479

10.  Safety testing of acellular pertussis vaccines: Use of animals and 3Rs alternatives.

Authors:  Marieke Hoonakker; Juan Arciniega; Coenraad Hendriksen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.